Ads
related to: cll latest developments in treatment list- FDA-Approved Treatment
Read About A Treatment For CLL
And Access Other Support Resources.
- Request A Representative
Fill Out A Brief Form To Request
A Representative.
- How To Order Brochure
Learn How To Order A Treatment
For Chronic Lymphocytic Leukemia.
- BTK Inhibitor Info
BTK Signaling Plays A Role In
Your Treatment. Learn More.
- Important Safety Info
View Clinical Data For A
CLL Therapy.
- Clinical Trial Data
See Efficacy Info On FDA-Approved
CLL Treatment.
- FDA-Approved Treatment
Search results
Results From The WOW.Com Content Network
Idelalisib (trade name Zydelig; codenamed CAL-101, GS-1101; PIK3CD inhibitor): FDA-approved in July 2014 for treatment of three types of blood cancers: treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in combination with rituximab, treatment of relapsed small lymphocytic lymphoma after at least two prior systemic therapies, and treatment of follicular lymphoma (FL) after ...
Idelalisib is a second-line medication for people whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab, [9] idelalisib is to be used in people for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions. [9]
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. [8] [9] In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell. [8] [9] Many people do not have any symptoms when they are first diagnosed. [8] [2] Those with symptoms may experience fevers, fatigue, night sweats, and ...
Treatment of people aged 12 years of age and older with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy [2]
In May 2016, a new indication for ibrutinib was approved in the United States for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). [31] In January 2017, a new indication for ibrutinib was approved in the United States for the treatment of adults with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require ...
Treatment can occasionally consist of "watchful waiting" (e.g., in CLL) or symptomatic treatment (e.g., blood transfusions in MDS). The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant.
Ads
related to: cll latest developments in treatment list